Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hypericin - Soligenix

Drug Profile

Hypericin - Soligenix

Alternative Names: SGX 301; VIMRxyn

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New York University; Weizmann Institute of Science
  • Developer Soligenix
  • Class Anthraquinones; Anti-inflammatories; Antidepressants; Antipsoriatics; Antivirals; Cytostatics; Perylenes; Polycyclic compounds; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Cell death stimulants; Photosensitisers; Singlet oxygen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cutaneous T-cell lymphoma
  • Discontinued Glioma; Hepatitis C; HIV infections; Hyperhidrosis; Kaposi's sarcoma; Psoriasis

Most Recent Events

  • 03 Dec 2019 Efficacy data from a phase II trial in Cutaneous T-cell lymphoma released by Soligenix
  • 03 Dec 2019 Soligenix completes enrolment in the phase III FLASH trial for Cutaneous T-cell lymphoma in USA
  • 11 Feb 2019 Hypericin is still in phase III trial for Cutaneous T-cell lymphoma in USA (Topical) (Soligenix pipeline, February 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top